NASDAQ: ELAB · Life Sciences · 5 alerts · CIK 1840563
Share price
$1.66Close, Nov 16
Market cap
$1.94M
Shares outstanding
1.17MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Pmgc Holdings Inc. filings on SEC EDGAR ↗
PMGC Holdings Inc. reported a significant revenue increase to $4.52 million for the nine months ended September 30, 2026, compared to $0.29 million in the prior year. However, net loss widened to $10.15 million due to increased operating expenses and interest costs, while the company underwent a series of reverse stock splits totaling 1-for-240.
PMGC Holdings announced results from a preclinical study of its engineered probiotic candidate EL-32, both as a standalone and in combination with semaglutide. The study identified a statistically significant greater absolute lean mass at the highest EL-32 dose compared to semaglutide alone, supporting the company's muscle-preservation thesis. While the combination improved insulin sensitivity and reduced body weight, it did not demonstrate a consistent additive metabolic benefit over semaglutide alone across all measures.
Pmgc Holdings Equity Investment of $1.84M in Nuclea Energy Canada Inc.
PMGC Holdings Inc. entered into a subscription agreement to invest $1.845 million in secured debentures of Nuclea Energy Canada Inc. The investment is part of a larger $9 million offering intended to fund Nuclea Canada's acquisition of assets from Moltex Energy Limited. The debentures are non-interest bearing, non-convertible, and mature in three months or upon certain corporate events.
PMGC Holdings Inc. (doing business as NorthStrive Holdings Inc.) filed a formal investor presentation slide deck and a specific deck related to its Maritime Defense Technology. The materials are intended for use in upcoming presentations to investors and analysts regarding the company's strategy and operations.
PMGC Holdings and its subsidiary NorthStrive Biosciences entered into a binding payment agreement with Longevity Health Holdings to secure royalty payments from the 2025 sale of the Elevai Skincare business. The agreement converts a 5% net sales royalty into scheduled monthly cash payments through August 2031, including interest and mandatory prepayments tied to future capital events. This restructuring provides PMGC with visible, non-dilutive cash flow while allowing it to focus on its core manufacturing and defense technology segments.